Outlook

Group and segment outlook 2024

Fresenius raises its outlook for FY/24¹ based on the excellent first quarter and improved prospects for the ramainder of the year.

For 2024, Group organic revenue growth² is now expected to grow between 4% to 7% (previous: 3% to 6%). Group constant currency EBIT^3,4 is expected to grow in the rage of 6% to 10% (previous: 4% to 8%). 

Fresenius Kabi now expects organic revenue growth in a mid-to high-single-digit percentage range in 2024 (previous: mid-single-digit percentage range). The EBIT margin⁴ is now expected to be in a range of 15% to 16% (previously: around 15%) (structural margin band: 14% to 17%). 

Improved Fresenius Helios outlook for FY/24: Following our Capital Markets Day in June 2024, Fresenius Helios now expects organic revenue to grow in a mid-single-digit percentage range in 2024 (previous: in a low to mid-single digit percentage range). The EBIT margin⁴ is now expected to be in a range of 10% to 11% (previous: within the structural margin band of 9% to 11%). 

The adjustment of the Group outlook also reflects the fact that the forecast is now given without Fresenius Vamed, i.e. exclusively for the Operating Companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed's rehabilitation business, Fresenius has initiated its structured exit from its Investment Company Fresenius Vamed.

 ¹ For the prior-year basis please see table “Basis for Guidance for 2024"
 ² 2023 base: €20,307 million
 ³ 2023 base: €2,266 million 
 ⁴ Before special items